



THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder
Collaboration to Advance Oncology
Therapeutics.

 info@cddf.org

 www.cddf.org

◎ WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in **Belgium** that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in **cancer drug development**.

◎ OUR MISSION

The CDDF's mission is to **facilitate collaboration between stakeholders**, to **increase efficiency in cancer drug development** and **accelerate the delivery of effective oncology treatment** to patients.

◎ HOW WE ADVANCE OUR MISSION

- ▶ The CDDF provides a **non-competitive, non-commercial platform** for **multi-stakeholder discussions** and **collaboration**
- ▶ The CDDF **brings together all actors** in the oncology community such as **academia**, the **pharmaceutical industry**, **regulatory authorities**, **HTAs**, **policymakers** and **patient advocacy groups**
- ▶ The CDDF **stimulates advancement and innovation** in the field through **scientific debate** and **open discussion**

INITIATIVES

For many years, the Cancer Drug Development Forum (CDDF) has stimulated discussions to **accelerate effective drug development** in oncology treatment and shorten time to market, and time to patient access.

The CDDF offers workshops, conferences and webinars that bring stakeholders involved in cancer drug development into a **productive dialogue in a neutral, non-competitive space**.

The association drives multiple activities and initiatives in **close contact with regulators** from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and national regulatory agencies, **HTAs, academic researchers** from around the globe, **pharmaceutical companies**, and **patient advocates**.





FACILITATE. DEBATE. ACTIVATE. INNOVATE.

The Cancer Drug Development Forum (CDDF) **Annual Conference** is a unique meeting which facilitates open, meaningful dialogue. This multi-stakeholder, interactive three-day gathering offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The agile, responsive nature of the CDDF platform allows **programs to be quickly initiated or adapted to reflect current and pressing issues**. The CDDF has also clearly proved to be a **visionary force within the cancer drug development field** addressing topics such as immuno-oncology, real-world data in cancer drug development, histology independent drug development and MRT & ctDNA in oncology, diversity in oncology clinical trials and the combination of immunotherapy and radiotherapy.

The CDDF continues to **pioneer progress in cancer drug treatments** through workshops and webinars exploring topics affecting the future of cancer care, such as real-world evidence, decentralised care and trials, drug and biomarker combinations, clinical research in Central and Eastern Europe and innovation in rare cancers.

The association also publishes **executive summaries, white papers and meeting reports** from workshops discussions, conference presentations and lecture briefings in order **to increase knowledge of the challenges and opportunities in cancer drug development**.

“

**CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAs, THE INDUSTRY,
ACADEMICS AND PATIENT
ADVOCATES TO
COLLABORATE**

”

**INCLUSIVE &
COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT**

CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs.

These distinguished academics, representing a range of perspectives within the drug development process, are experienced pre-clinical and clinical investigators, medical oncologists, statisticians, and immunologists, who have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS



**Ruth
Plummer**

Chairperson



**Eva
Skolvlund**

Vice-Chairperson



**Axel
Glasmacher**

Treasurer



**Jaap
Verweij**

Managing Director



**Catarina
Edfjaell**



**Mark
Lawler**



**Stefan
Symeonides**



**Rosa
Giuliani**



**Christian
Schneider**



**Fergus
Sweeney**

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.



**Marjorie
Recorbet**

Director of
Operations



**Giorgia
Campagnano**

Event Manager



**Caroline
Marissal**

Event Coordinator



**Hyunmin
Park**

Community &
Communication
Coordinator



CDDF ACTIVITIES 2024

Click the buttons to view detailed information

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2024

*Changing paradigms
to accelerate
oncology drug
development*

5-7 February 2024
Noordwijk aan Zee, NL



[Programme](#)

[Executive
summary](#)



MULTI-STAKEHOLDER WORKSHOP

**Clinical Research in
Central and Eastern
Europe**

15 - 16 April 2024
Krakow, PL



[Programme](#)

[Registration](#)



#ESMO24

ESMO CONGRESS 2024 -
EDUCATIONAL SESSION

**ESMO-CDDF:
Regulatory Challenges in
Clinical Cancer Drug
Development**

Monday 16 September 2024
08:30-10:00 CET,
CC5 - Zaragoza Auditorium



[Programme](#)

[Registration](#)



CDDF & EORTC JOINT WORKSHOP

**Innovation and Access
in Rare Cancers**

23-24 September 2024
Amsterdam, NL



[Programme](#)

[Save the date](#)

CDDF ACTIVITIES 2024

CDDF WEBINAR SERIES



LIVE WEBINAR

COVID-19 and Cancer - Time for a Reset to repair the damage done

Ajay Aggrawal (Guy's and St Thomas' NHS Foundation Trust)
Debbie Keatlely (Cancer Research UK)

15 January 2024
17:00-18:00 CET



[Recording/slides](#)

[Takeaways](#)



LIVE WEBINAR

Clinical Research in Central and Eastern Europe

Susan Bhatti (Merck BV, NL)
Mark Lawler (CDDF, UK)
Wiktor Janicki (AstraZeneca, PL)

Monday 12 February 2024
17:00-18:00 CET



[Recording/slides](#)

[Takeaways](#)

Webinar Topics for 2024

- Bayesian Statistics in Cancer Drug Development (29 April 2024)
- Cancer Medicines Forum (25 June 2024)
- Big data / AI
- Follow-up webinar on EU HTA regulation
- EU Clinical Trials Regulation

MEETING OUTCOMES 2023

Click the buttons to view meeting outputs

► CDDF Annual Conference 2023: **Challenges in Clinical Trial Performance** (6 – 8 February 2023, NL)

[Executive summary](#)

[Meeting report](#)

[Recordings/slides](#)

► Multi-Stakeholder Workshop: **Dose Optimisation in Early Oncology Drug Development** (3 – 4 April 2023, NL)

[Executive summary](#)

[White paper \(available soon\)](#)

[Recordings/slides \(member only*\)](#)

► Multi-Stakeholder Workshop: **Innovative Oncology Trial Designs** (18 – 19 September 2023, NL)

[Executive summary](#)

[White paper \(available soon\)](#)

[Recordings/slides \(member only*\)](#)

► Multi-Stakeholder Workshop: **The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology** (13-14 November 2023, NL)

[Executive summary](#)

[White paper \(available soon\)](#)

[Recordings/slides \(member only*\)](#)

**Recent meeting recordings and slides are accessible exclusively to the CDDF Industry Members, the CDDF Full Association Member, Patient Advocates, HTAs, and regulators (FDA, EMA, HTAs and national agencies) for educational purposes*

MEETING OUTCOMES 2023

Click the buttons to view meeting outputs

- **CDDF Live Webinar:**
**Immunotherapy and Radiotherapy
Combinations Part 2: Regulatory
Considerations**
(27 February 2023)

[Key takeaways](#)

[Recordings/slides](#)

- **CDDF Live Webinar:**
**Development of Novel and Targeted
Agents in Precision Cancer
Prevention and Interception**
(15 June 2023)

[Key takeaways](#)

[Recordings/slides](#)

[Meeting report](#)

- **CDDF Live Webinar:**
**Beating Cancer In Europe – Time
to Deliver**
(10 July 2023)

[Key takeaways](#)

[Recordings/slides](#)

[Meeting report](#)

- **CDDF Live Webinar:**
**Critical Impacts of the In Vitro
Diagnostic Regulation (IVDR)
Implementation on Patient Access
to Clinical Trials**
(7 September 2023)

[Key takeaways](#)

[Recordings/slides](#)


- **CDDF Live Webinar:**
**Perspectives on the New EU
Health Technology Assessment
(HTA) Regulation 2021/2282**
(28 September 2023)

[Key takeaways](#)

[Recordings/slides](#)



CDDF INDUSTRY MEMBERS PLATFORM



WHAT IS THE CDDF INDUSTRY MEMBERS' PLATFORM?

The CDDF Industry Members' Platform is composed of large and SME members from the pharmaceutical industry who support the CDDF in its mission to establish a neutral space for stakeholders to facilitate discussion on innovative drug development in oncology.

The Industry Members' Platform acts as an advisory body within the CDDF. It supports the association in compliance with all relevant regulations in a manner consistent with the non-competitive, non-commercial platform that the CDDF offers to all stakeholders.

WHY JOIN THE CDDF INDUSTRY MEMBERS' PLATFORM?



Stimulate advancement in oncology treatment and delivery

Identify and overcome challenges in the development of cancer drugs



Improve product time to market for new treatments




CONTRIBUTE TO THE **DEVELOPMENT OF CANCER DRUGS AND TREATMENTS**





BECOME A MEMBER OF THE CDDF



INDUSTRY MEMBER BENEFITS

1

Unique Platform for Multi-Stakeholder Discussions

Access to the CDDF Industry Members' Platform to join industry members in addressing challenges in cancer drug development from a multi-stakeholder perspective



2

Complimentary Registration

Complimentary registration for in-person participants at every CDDF hybrid event (*one for small businesses, two for medium-sized enterprises and four for large pharmaceutical companies*).



3

Livestream Access

Livestream access to all CDDF conferences, workshops and webinars.



4

Early Access to Digital Content

Early access to digital content from the CDDF's conference, workshops and webinars before public release.





BECOME A MEMBER OF THE CDDF



INDUSTRY MEMBER BENEFITS

5

Professional Contribution

Professional contribution to CDDF's scientific programme and the chance to collaborate with various stakeholders on developing content for CDDF meetings.



6

Access to a Reputable Oncology Network

Access to a reputable oncology network and opportunities to connect informally with representatives from academia, regulatory authorities, HTAs, and patient groups.



CDDF BREAKS DOWN SILOS
IN THE ONCOLOGY COMMUNITY AND
FACILIATES OPEN, MEANINGFUL DIALOGUE
AMONG ALL STAKEHOLDERS



CDDF INDUSTRY MEMBERSHIP PACKAGES



Start-up or small business



Medium-sized enterprise



Large Pharmaceutical company

Criteria	No oncology product on the market <u>and</u> Revenues ≤ € 50 million	Either low revenues <u>and</u> at least one oncology product on the market or medium or large revenues <u>and</u> no oncology product on the market	At least one oncology product on the market <u>and</u> Revenues ≥ € 1 billion
Annual contribution	€ 7700	€ 19 800	€ 44000



BENEFITS

Access the CDDF Industry Members Platform	✓	✓	✓
Free registration for every CDDF event	1	2	4
Livestream access to CDDF workshops and conference	5	15	Unlimited
Early access to digital content from the CDDF discussions before public release	5	15	Unlimited
Contribution to CDDF's scientific programme and collaboration with multi-stakeholders	✓	✓	✓



COLLABORATION AND OPEN DIALOGUE AMONG ALL STAKEHOLDERS ARE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS





 info@cddf.org

 www.cddf.org

 [@cddf_eu](https://twitter.com/cddf_eu)

 [The Cancer Drug Development Forum \(CDDF\).](https://www.linkedin.com/company/cddf/)

 Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

 The CDDF is a non-profit association in the register of legal entities at the French
Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752